Semaglutide is a long-acting GLP?1 receptor agonist peptide modified with fatty acid side chain. Different from short half-life native GLP-1, the fatty acid moiety enables reversible binding to albumin in biological fluids, greatly extending its retention time, which makes it a classic research compound for peptide pharmacokinetics and sustained-release formulation exploration.

Common laboratory research directions include in vitro receptor activation screening, glucose tolerance tests in animal models, appetite and energy intake related mechanism research. Researchers also carry out stability tests and delivery system optimization to explore peptide preservation and administration strategies. The peptide sequence is engineered to resist cleavage by dipeptidyl peptidase 4 (DPP?4), maintaining bioactivity in biological environments.

Synthesized by solid-phase peptide synthesis, purified by reversed-phase high-performance liquid chromatography and then lyophilized. Freeze-dried powder protects the peptide backbone and lipid modification from hydrolysis. After reconstitution, divide the solution into single-use aliquots. Repeated freeze-thaw cycles will break molecular structure and reduce biological activity. Operations of weighing and reconstitution should be finished under low humidity condition.